Physician profile
Amy E Bentley
NPI 1467496885
$3,164.56
in general payments reported to CMS, 2019-2025
28 companies · $743 in 2025
The $743 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.06 · 2021: $60.26 · 2022: $556 · 2023: $680 · 2024: $1,111 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,517 · Education: $18.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.66 |
| Education | $18.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $673.73 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $484.46 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $397.67 | 2022-2025 | |
| Abbvie INC. | $241.73 | 2021-2025 | Vraylar |
| Xeris Pharmaceuticals, INC. | $213.25 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Lilly USA, LLC | $205.71 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.85 | 2022-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $109.71 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $87.91 | 2024-2025 | Airsupra, Enhertu |
| Astellas Pharma US INC | $85.68 | 2023-2025 | Veozah |
| Amgen INC. | $77.79 | 2023-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $49.79 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $38.45 | 2024-2025 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $30.48 | 2022-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.66 | 2024 | Ofev |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $29.40 | 2021-2023 | Xarelto |
| Exact Sciences Corporation | $27.71 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $27.50 | 2025 | Eluvia |
| Cook Medical LLC | $20.63 | 2024 | Zenith |
| Radius Health, INC. | $19.79 | 2021 | |
| Eisai INC. | $19.44 | 2025 | |
| Lifescan, INC. | $19.35 | 2022 | |
| Lundbeck LLC | $18.85 | 2022 | |
| Abbott Laboratories | $18.36 | 2025 | Eterna |
| Sanofi-Aventis U.S. LLC | $14.75 | 2023 | |
| Medtronic Vascular, INC. | $13.06 | 2020 | |
| Medtronic, INC. | $12.67 | 2021 | |
| Inogen, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Bentley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.